Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Authors
Keywords
-
Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 388, Issue 1, Pages 44-54
Publisher
Massachusetts Medical Society
Online
2022-12-22
DOI
10.1056/nejmoa2212419
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)
- (2022) Sai-Hong Ignatius Ou et al. JOURNAL OF CLINICAL ONCOLOGY
- Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer
- (2022) Marwan Fakih et al. ONCOLOGIST
- Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.
- (2022) Joel W. Neal et al. JOURNAL OF CLINICAL ONCOLOGY
- KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy
- (2022) Meagan B. Ryan et al. Cell Reports
- Distribution of KRASG12C Somatic Mutations across Race, Sex, and Cancer Type
- (2021) Amin H. Nassar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
- (2021) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Enhancing the landscape of colorectal cancer using targeted deep sequencing
- (2021) Chul Seung Lee et al. Scientific Reports
- Acquired Resistance to KRASG12C Inhibition in Cancer
- (2021) Mark M. Awad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Strategies to tackle RAS-mutated metastatic colorectal cancer
- (2021) G. Patelli et al. ESMO Open
- Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
- (2021) Marwan G Fakih et al. LANCET ONCOLOGY
- KRAS G12C metastatic colorectal cancer: specific features of a new emerging target population
- (2020) Marta Schirripa et al. Clinical Colorectal Cancer
- Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
- (2020) Jay B. Fell et al. JOURNAL OF MEDICINAL CHEMISTRY
- EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer
- (2020) Vito Amodio et al. Cancer Discovery
- Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment
- (2020) Marloes Zoetemelk et al. MOLECULES
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the untargetable KRAS in cancer therapy
- (2019) Pingyu Liu et al. Acta Pharmaceutica Sinica B
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
- (2019) Scott Kopetz et al. NEW ENGLAND JOURNAL OF MEDICINE
- The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- (2019) Jill Hallin et al. Cancer Discovery
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- PIK3CA mutation and colorectal cancer precision medicine
- (2017) Tsuyoshi Hamada et al. Oncotarget
- Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
- (2016) D. P. Modest et al. ANNALS OF ONCOLOGY
- Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
- (2016) P. Lito et al. SCIENCE
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- (2015) Robert J. Mayer et al. NEW ENGLAND JOURNAL OF MEDICINE
- KRAS Protein Stability Is Regulated through SMURF2: UBCH5 Complex-Mediated β-TrCP1 Degradation
- (2015) Shirish Shukla et al. NEOPLASIA
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More